Renew Labs Achieves Prestigious Accreditation by CAP, Setting New Standards in Clinical Laboratory Services

Renew Labs Achieves Accreditation from the College of American Pathologists

Renew Labs, the clinical laboratory division of Renew Biotechnologies, has recently received prestigious accreditation from the College of American Pathologists (CAP). This recognition affirms the company's dedication to maintaining high standards in laboratory quality and operational excellence following a thorough inspection.

CAP accreditation is often seen as a hallmark of proficiency in the medical laboratory field. The program is designed to ensure laboratories uphold rigorous benchmarks across various areas, including testing operations, quality systems, personnel qualifications, and overall management. For Renew Labs, achieving this accreditation represents a significant milestone, reinforcing its mission of developing advanced laboratory capabilities grounded in clinical quality, reproducibility, and regulatory compliance.

Ki Aston, the Laboratory Director at Renew Labs, emphasized the importance of this achievement, stating, "CAP accreditation reflects the strength of our laboratory systems and the discipline our team brings to every part of the testing process." He also noted that as the company continues to broaden its sequencing and molecular profiling capabilities, adhering to rigorous quality standards will remain central to their support for patients, healthcare providers, and partners.

Renew Biotechnologies is known for its extensive offerings in sequencing, molecular testing, and assay development, with a particular emphasis on advanced methods like long-read and native-read sequencing. This recent CAP accreditation not only bolsters Renew Labs' credibility but also enhances its ability to collaborate with a wide range of partners within the realms of research, clinical product development, and laboratory testing focused on patient health.

Steve Abbott, the Chief Operating Officer of Renew Biotechnologies, remarked, "Renew Labs was built to bring advanced biology into a laboratory environment that can support real clinical impact. This accreditation reinforces that quality is the foundation behind the services, technologies, and programs we are advancing through Renew's platforms." This commitment to quality underpins the company's ability to effectively support biotechnology, biopharma, clinical research, and translational teams who are striving to bring complex molecular applications from the research phase to practical clinical use.

Renew Labs' achievement of CAP accreditation is indicative of its ongoing growth and impact within the sector. With a strong focus on innovation and quality, the company aims to continue pushing the boundaries of what's possible in laboratory services for medical diagnostics and patient care.

To learn more about the range of services offered by Renew Biotechnologies, which include sequencing, molecular testing, assay development, and clinical laboratory services, visit their official website. Renew is committed to shaping the future of diagnostics and research by transforming complex biological signals into meaningful clinical applications that benefit patients and healthcare systems alike.

About Renew Biotechnologies

Renew Biotechnologies is at the forefront of developing next-generation diagnostics driven by sequencing technologies. The company utilizes both native and long-read sequencing methods coupled with specialized workflows in a CAP-accredited and CLIA-certified laboratory environment, aimed at converting intricate biological data into research assays, clinical products, and scalable programs designed to enhance patient care.